Assenagon Asset Management S.A. Increases Position in Glaukos Co. (NYSE:GKOS)

Assenagon Asset Management S.A. grew its holdings in shares of Glaukos Co. (NYSE:GKOS) by 31.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 75,798 shares of the medical instruments supplier’s stock after purchasing an additional 18,067 shares during the period. Assenagon Asset Management S.A. owned approximately 0.15% of Glaukos worth $9,875,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Natixis purchased a new position in Glaukos during the first quarter valued at $614,000. Vanguard Group Inc. raised its position in shares of Glaukos by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock worth $500,576,000 after purchasing an additional 72,159 shares during the last quarter. UniSuper Management Pty Ltd bought a new position in Glaukos in the 1st quarter worth about $913,000. Duality Advisers LP purchased a new stake in Glaukos during the 1st quarter valued at about $3,476,000. Finally, Lisanti Capital Growth LLC bought a new stake in Glaukos during the 1st quarter valued at about $3,969,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Aimee S. Weisner sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the transaction, the director now owns 30,119 shares of the company’s stock, valued at $3,614,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,250 shares of company stock valued at $4,825,873. 6.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GKOS. Piper Sandler set a $140.00 price target on shares of Glaukos in a report on Thursday, October 17th. Wells Fargo & Company increased their target price on Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. BTIG Research boosted their price target on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Stifel Nicolaus increased their price objective on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Citigroup lowered Glaukos from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $130.00 to $132.00 in a research report on Wednesday, July 10th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average target price of $130.45.

Glaukos Stock Up 0.1 %

Shares of GKOS stock opened at $130.59 on Monday. The company has a 50 day simple moving average of $129.07 and a two-hundred day simple moving average of $118.41. The stock has a market cap of $6.58 billion, a P/E ratio of -45.34 and a beta of 1.02. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $136.60. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). The company had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. Glaukos’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.55) earnings per share. On average, research analysts expect that Glaukos Co. will post -2.16 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.